Following the success of our 2024 International User Group Meeting, OncoDNA is bringing its community together once again in 2025. This year, we invite you to Cologne for an event focused on collaboration, shared expertise, and overcoming challenges in implementing Comprehensive Genomic Profiling (CGP) in routine laboratory workflows.
At OncoDNA, we believe that genomics is easier when we work together—when laboratories, clinicians, and industry partners connect to exchange knowledge, share best practices, and find solutions that make precision oncology more accessible and impactful. The meeting will be conducted entirely in English to accommodate the diverse nations attending
Limited Places
Lindner hotel Köln City Plaza (Germany)
This event is tailored for Genomic Laboratory Staff, including Professors, Researchers, Heads of Service, Clinical Scientists, Bioinformaticians, Lab Technicians, and more.
It also welcomes Genomic Purchasing Staff, such as buyers, commercial leads, procurement specialists, and distributors, to discuss the latest trends and solutions in genomic technologies.
Lastly, the event is ideal for Oncologists and Nursing Staff with an interest in genomics, providing a platform to explore the cutting-edge applications of genomics in oncology care.
Subject to updating as speakers become available.
| Event | Time | Details | Speaker(s) |
|---|---|---|---|
| Delegate Arrival | 13:30 – 14:00 | Arrival and light lunch available following travel, opportunity to check into hotel etc. Tea and Coffee provided | |
| Welcome | 14:00 – 15:15 | A warm welcome from OncoDNA, including an anonymised profile of ‘Who is in the room’ Delegates will hear a summary of last years user group, have an opportunity to make introductions and hear why the patient continues to be the reason for us all to improve how we deliver CGP services overtime | Jean-Pol Detiffe – Founder and Chief Innovation Officer at OncoDNA |
| Finding the Sweet Spot Between Comprehensive and Targeted Sequencing in Clinical Cancer Care – A customer perspective | 15:15 – 16:00 | Consider the benefits and challenges with implementing a comprehensive genomic profiling solution Including how to choose the right tool for the job with clinical examples. Ensuring that laboratory capacity can meet demand to provide the best patient care all with within the constraints of working within the English NHS | To be confirmed |
| Why choose OncoDEEP? – A customer perspective | 16:00 – 16:45 | HRD testing was previously funded by a global co-promotion agreement between AZ ad MSD and delivered in accordance with arrangements agreed with NHS England (NHSE) through the 7 Genomic Hubs by Myriad Genetics Inc in the United States. This arrangement ceased at the end of March 2024 from which point NHSE commenced funding the service directly. Hear how OncoDEEP also solved the problem of the HRD challenge, how this customer validated the HRD element of OncoDEEP and transitioned their service. | Katya Mokretar -Deputy Operations Lead/Clinical Scientist Cancer Genetics. NHS South East Genomic Medicine Service. |
| The role of ‘Guardian Angels’ in ensuring customers can successfully use the OncoDEEP kit. – OncoDNA | 16:45 – 17:00 | Learn that whatever the size or shape of your laboratory the need for a is instrumental for success -take away the key elements of that plan and how to amend it to make it work for your laboratory working closely with OncoDNA’s Field Applications Specialists | Jean-Francois Vanbellinghen – Field Application Specialist, OncoDNA |
| Comfort Break | 17:00 – 17:20 | Delegates have the opportunity to ‘check in’ and find their rooms etc if not already done so! | |
| Networking and drinks – Finding kindred spirits using the OncoDEEP kit | 17:20 – 18:45 | Five-minute profile – Micro poster presentations by organisation like ‘speed dating’ – find your ‘person/organisation that you want to work with during Day two | |
| Closing Remarks and Introduction to Customer Awards | 18:45 – 19:00 | ‘Wrap up’ – Reflections from Day One/Introduction to ‘why’ OncoDNA is launching its customer awards. In that the company recognises that across its customer base that people/organisations do not want not to ‘rework the wheel’ and wish to continually improve their use of the OncoDEEP kit. | Adriana Terrádez – Chief Commercial Officer at OncoDNA |
| Dinner | 19:00 – 22:00 | Networking dinner |
| Event | Time | Details | Speaker |
|---|---|---|---|
| Delegate Arrival & Refreshments | 08:45 – 09:15 | Delegates seat themselves throughout Day 2 so they can work alongside other people/organisations they have met on Day one. | |
| OncoDEEP Kits and learnings from our customers | 09:15 – 10:00 | OncoDEEP is a total solution to which has been designed and delivered to facilitate an efficient workflow detecting variants and complex biomarkers and providing a clinical report | Koenraad Eycken – Chief Product Officer at OncoDNA |
| Customer presentation | 10:00 – 10:45 | Scaling up from a small sized panel to CGP for the first time can present challenges. Hear the experience from the perrspective of a smaller sized lab adopting CGP for the first time and finding the balance between funding and reimbursement | To be confirmed |
| Comfort Break / coffee/Delegates move to first break out session | 10:45 – 11:00 | ||
| Deconstructing the OncoDEEP Kit workflow | 11:00 – 11:45 | 1.Automation and the wetlab | To be confirmed |
| (small group work x3 in parallel) | 11:00 – 11:45 | 2.Data analysis and BioIT | To be confirmed |
| (3 x 45 mins) delegates sign up to one of the choices | 11:00 – 11:45 | 3.Reporting using OncoKDM and improving the quality of Multidisciplinary Team Meetings | Dr Cheng Boon – Medical Director OncoDNA and practising oncologist |
| Delegates move to second break out session | 11:45 – 12:00 | ||
| Quality is never an accident | 12:00 – 12:45 | 1.Monitoring sample quality using CDI dashboard | Dr. Marcel Trautmann – Gerhard -Domagk-Institute of Pathology I University Hospital Münster (UKM) |
| (small group work x 3 in parallel) delegates sign up to one | 12:00 – 12:45 | 2.Evaluating impact of OncoDEEP performance using different sequencing platforms | To be confirmed |
| (3 x 45 mins) | 12:00 – 12:45 | 3.Monitoring OncoDEEP Performance (Thresholdsfor HRD, TMB and MSI partipation in EQA Schemes and Ringtrials | To be confirmed |
| Lunch | 12:45 – 13:30 | ||
| Laboratory workforce and business continuity | 13:30 – 14:00 | A laboratories success in the use of OncoDEEP kits is directly related to the quality of people you recruit, grow and develop. Plan how to train and maintain training in the use of the OncoDEEP Kit whilst also navigate workforce shortages and maintain business continuity | To be confirmed |
| Flexible and Innovative | 14:00 – 14:30 | On a practical note, delegates hear how OncoDNA is innovating around the solid and liquid workflow creating an economically viable, fully optimised, high throughput CGP service. | To be confirmed |
| Customer Award 2025 and the patient voice | 14:30 – 15:15 | Customer awards and why patients need data to help inform decisions relating to treatment and care | To be confirmed |
| Conference Summary & Closing Remarks | 15:15 – 15:30 | OncoDNA strategy, how to get involved with the companies vision and with projects as they emerge, reflections on the 2nd User Group Conference from the founder of OncoDNA | Jean-Pol Detiffe – Founder and Chief Innovation Officer at OncoDNA |
. Knowledge sharing:
Disseminate customers experience of using the OncoDEEP kit in different laboratory settings from presentations, poster sessions and networking
· Standard protocols:
Agree plans on how to implement the OncoDEEP Kit, the validation methodology and how to monitor test quality once your service is ‘live’
· Multi-platform evaluation
Learn how the OncoDEEP kit performs on different sequencing platforms
· Data and reporting analysis
‘Deep dive’ into OncoDEEP sequencing data and learn how to optimise reporting using OncoKDM reducing effort and duplication of work.
· Streamlined laboratory workflows
Learn how to automate the OncoDEEP kit workflow to improve efficiency, quality and productivity.
· Collaboration opportunities:
Identify new projects at OncoDNA which provide customers with additional exciting ways of working together/with the company.
· Customer success
Participate in customer awards and help the winners receive recognition for their work in optimising use of the OncoDEEP (details of how to enter will be announced in April)
Dr. Katya Mokretar is a Clinical Scientist specializing in molecular oncology, with expertise in leukemia diagnostics and measurable residual disease (MRD) monitoring. Currently serving as Deputy Operations Lead in the Molecular Oncology Unit at Guy’s Hospital, she has extensive experience in next-generation sequencing (NGS) assays for diagnosing hematological malignancies. Her career spans roles in leading cancer genetics departments, where she has advanced genomic diagnostic tools for both leukemia and solid tumors. Dr. Mokretar is a member of prominent scientific organizations, including the European Haematology Association and British Society of Genetic Medicine (Synnovis)
Dr. Marcel Trautmann is a highly regarded expert in the field of molecular diagnostics and precision oncology. With a robust background in medical research and clinical applications, he has made significant contributions to the integration of advanced genomic technologies into clinical practice. Dr. Trautmann is particularly noted for his work on optimizing next-generation sequencing (NGS) workflows and developing business cases for the adoption of comprehensive genomic profiling (CGP) in laboratories. Dr. Trautmann’s expertise, coupled with his dedication to advancing precision medicine.
Dr. Cheng Boon is a highly skilled Consultant Oncologist with extensive experience in the field of oncology. Currently, Dr. Boon serves as a Consultant Oncologist at the University Hospitals of Derby and Burton NHS Foundation Trust, where he has been a key part of the team since June 2023. His role here involves providing expert care to cancer patients, collaborating with multidisciplinary teams, and advancing treatment protocols.
In addition to his position at Derby and Burton, Dr. Boon also holds a full-time consultant role at The Royal Wolverhampton NHS Trust. His work at this esteemed institution further demonstrates his commitment to delivering exceptional care and contributing to the advancement of oncological practices.
With a strong scientific background, he has founded several companies focused on life sciences and health technologies. His career is marked by a deep commitment to innovation, particularly in developing cutting-edge diagnostic tools and solutions that enhance healthcare outcomes. Detiffe is known for his leadership and ability to bridge the gap between scientific research and practical applications in the industry.
Nicola Foot is a dedicated professional in the field of genomics, with expertise in developing innovative strategies for genomic technologies. With experience at the intersection of science and business, Nicola has a proven track record in driving projects from concept to implementation, fostering collaboration across teams, and advancing cutting-edge solutions in the genomics space. Passionate about translating scientific knowledge into real-world applications, Nicola is committed to pushing the boundaries of personalized healthcare and research.
Philip joined Step Pharma in June 2021 and was promoted from Vice President, Head of Research & Translation Medicine to Chief Scientific Officer in January 2021. Prior to this, he held senior leadership roles in biotech and biopharma companies, overseeing oncology drug development and biomarker discovery programmes. He is a cofounder of Gabriel Precision Oncology, a clinical software company also focused on improving outcomes for those living with cancer. Philip is a board-certified haematologist with over 16 years of frontline healthcare experience as well as biopharmaceutical industry experience, particularly in translational medicine, drug development, and biomarker discovery.
Philip is a Member of the Royal College of Physicians, UK, and a Fellow of the Royal College of Pathologists, UK. He holds a PhD in molecular cancer biology from the University of Cambridge, UK. Following this he conducted post-doctoral research studies at the BC Cancer Agency, Vancouver, Canada, and has more than 100 peer-reviewed publications. Philip is an Honorary Professor of Translational Medical at the Hull York Medical School, UK.
Sébastien Sauvage is a dedicated professional at OncoDNA, specializing in the integration of genomic data and personalized cancer care solutions. With a background in engineering and biotechnology, Sébastien plays a pivotal role in developing cutting-edge diagnostic tools that empower oncologists to make informed treatment decisions. His expertise in project management, data analysis, and innovative healthcare solutions helps drive advancements in precision oncology, ultimately improving patient outcomes.
Magnusstraat 20 , D-50672 Cologne, Germany
Please quote reference O044 if you wish to stay at this hotel as it will provide you with a discount for your stay. When the booking will be secured the clients will receive an email with their confirmation number, and the room number will be assigned at the time of check-in from our Frond office team.
Seats are limited for the OncoDEEP Kit European user meeting.
You can reserve multiple spots at once. After completing the payment process, you’ll be prompted to enter individual details, confirm attendance at the evening dinner, and specify any dietary restrictions.
Company
OncoDNA S.A. (headquarters)
Rue Louis Breguet 1
BE-6041 Gosselies
Links
Support
